Lung Cancer Clinical Trials in Anaheim, CA

Lung Cancer Clinical Trials in Anaheim, CA

View the best 10 lung cancer medical studies in Anaheim, California. Access promising new therapies by applying to a Anaheim-based Lung Cancer clinical trial.

Trials in Anaheim, California

Here are the top 10 medical studies for lung cancer in Anaheim, California

Image of Hematology Oncology Associates of CNY, PC in East Syracuse, United States.

Adagrasib

Small Molecule Drug

Recruiting1 awardPhase 2
This trial tests a drug combo to treat advanced lung cancer with a genetic mutation.
Image of Research Site - Orange City in Orange City, United States.

HLX10

Monoclonal Antibodies

Verified
Recruiting3 awardsPhase 3
This trial is testing two different treatment combinations for patients with extensive-stage small cell lung cancer who have not received any prior treatment. One group will receive a new drug called Serplulimab along with standard chemotherapy, while the other group will receive an existing drug called Atezolizumab with the same chemotherapy. Both immunotherapy drugs aim to help the immune system fight cancer, and the chemotherapy drugs work by killing cancer cells. Atezolizumab has been shown to improve survival in small-cell lung cancer when combined with chemotherapy, changing the standard first-line therapy.
Image of Next Oncology in Fairfax, United States.

CBP-1019

Bi-specific Ligand Conjugated Drug

Recruiting1 awardPhase 1 & 2
This trial is testing CBP-1019, a drug that targets cancer cells, in patients with advanced solid tumors who have no other treatment options. The drug works like a guided missile, finding and attacking cancer cells more precisely.
Image of UC Irvine Health in Orange, United States.

Lorlatinib

Recruiting3 awardsPhase 4
This trial aims to continue providing lorlatinib to patients who are still benefiting from it. Lorlatinib is a medication that helps stop cancer cells from growing. The trial will also collect more safety data to better understand any side effects. Lorlatinib is used to treat non-small-cell lung cancer with ALK or ROS1 rearrangement, and it has been studied to assess its safety and effectiveness.
Image of Alta Bates Summit Medical Center-Herrick Campus in Berkeley, United States.

N-803 (ALT-803) +1 More

Immunostimulant

Recruiting1 awardPhase 2 & 3
This trial is testing a new combination of treatments for patients with advanced lung cancer. The treatments aim to boost the immune system's ability to fight cancer and prevent it from growing. The goal is to see if this combination can help patients live longer compared to standard treatments.
Image of Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine in Orange, United States.

Osimertinib +1 More

Tyrosine Kinase Inhibitor

Recruiting1 awardPhase 1 & 2
This trial is studying the side effects and best dose of EMB-01 when given with osimertinib for patients with EGFR-mutant non-small cell lung cancer that has progressed on standard treatment.
Image of Research Site in Mesa, United States.

Durvalumab +1 More

Checkpoint Inhibitor

Recruiting1 awardPhase 3
This trial is testing a new immunotherapy drug combo to see if it's more effective than just one of the drugs for treating lung cancer that has spread and can't be removed by surgery.
Image of The Oncology Institute of Hope and Innovation in Whittier, United States.

Pembrolizumab +1 More

Monoclonal Antibodies

Recruiting2 awardsPhase 3
This trial will compare the effectiveness of a new cancer drug, datopotamab deruxtecan, when used with pembrolizumab versus pembrolizumab alone in patients with advanced lung cancer.
Image of 1004 in Denver, United States.

BDTX-1535

Small Molecule Inhibitor

Recruiting1 awardPhase 1 & 2
This trial is testing a new drug for people with glioblastoma or non-small cell lung cancer who have disease progression following standard of care.
Image of Illinois Cancer Care in Peoria, United States.

Zimberelimab +7 More

Monoclonal Antibodies

Recruiting2 awardsPhase 3
This trial is testing two new drugs, zimberelimab and domvanalimab, combined with chemotherapy for patients with advanced lung cancer that has spread and lacks specific genetic targets. These drugs help the immune system better recognize and attack cancer cells. The goal is to see if this combination improves survival compared to another drug, pembrolizumab, with chemotherapy.

Phase 3 Trials

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.